MedPath

Assessing Hydration Status With a Wearable Bioimpedance Sensor in Elderly Individuals

Not Applicable
Recruiting
Conditions
Dehydration
Interventions
Device: Wearable bioimpedance sensor
Registration Number
NCT05831800
Lead Sponsor
Mode Sensors AS
Brief Summary

This is a single-arm prospective study, investigating the feasibility, usability, and safety of a wearable bioimpedance sensor in elderly individuals. The sensor is applied on the upper back of the subject, and will be replaced once weekly. The study will include four phases, each interspersed by an interim analysis. Each phase will have a duration of four weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Age ≥ 60 years
Exclusion Criteria
  • Known allergies or skin sensitivities to electrode hydrogel and/or acrylic-based adhesives
  • Non-intact skin such as skin breakdown where the device is to be placed (upper back)
  • Implantable pulse generators such as pacemakers and defibrillators
  • Any medical or psychiatric condition, which in the opinion of the investigator precludes participation

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Wearable bioimpedance sensorWearable bioimpedance sensor-
Primary Outcome Measures
NameTimeMethod
Mean use time of the wearable sensorUp to 7 days
Secondary Outcome Measures
NameTimeMethod
Clinical assessment of hydration statusDay 1, 8, 15, 22, 29
The mean number of days the sensor provides valid measurementsUp to 7 days
Frequency and severity of adverse device effectsDay 1-30
Stability of device measurements following weekly patch replacementDay 8, 15, 22, 29

Test-retest reliability of the investigational device will be investigated by assessing the correlation between impedance measurements (in Ohm) before and after device replacement.

Mean and standard deviation of the device output variablesUp to 7 days
User satisfactionDay 8, 15, 22, 29

Will be assessed using a likert scale from 1-5, where 1 represents "strongly disagree" and 5 represents "strongly agree".

Trial Locations

Locations (1)

Tempe Helse- og velferdssenter

🇳🇴

Trondheim, Norway

© Copyright 2025. All Rights Reserved by MedPath